Since host cells are the target in this study, in contrast to the usual focus on tumor-targeted therapy, a therapy developed to inhibit CLIC4 function in the host would be less likely to develop resistance as occurs in targeting heterogeneous and genomically unstable cancer cells. Here, CLIC4 is linked to neoplasm.